

# CITATION REPORT

List of articles citing

The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study

DOI: 10.1016/j.ejheart.2005.01.022

European Journal of Heart Failure, 2005, 7, 537-41.

**Source:** <https://exaly.com/paper-pdf/38735270/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
211	The diagnosis and management of chronic heart failure in the older patient. <b>2005</b> , 75-76, 49-62		11
210	Is electrocardiography still useful in the diagnosis of cardiac chamber hypertrophy and dilatation?. <b>2006</b> , 24, 401-11, ix		5
209	B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure. <b>2006</b> , 370, 174-9		36
208	Diagnostic usefulness of B-type natriuretic peptide and functional consequences of muscle alterations in COPD and chronic heart failure. <b>2006</b> , 130, 1220-30		7
207	B-type natriuretic peptides as powerful markers in cardiac diseases [analytical and clinical aspects / B-Typ natriuretische Peptide als aussagekräftige Marker bei kardialen Erkrankungen [Analytische und klinische Aspekte. <b>2006</b> , 30, 165-184		
206	Assay for measurement of intact B-type natriuretic peptide prohormone in blood. <b>2006</b> , 52, 1054-61		112
205	B-type natriuretic peptides as powerful markers in cardiac diseases: Analytical and clinical aspects. <b>2006</b> , 25, 287-308		
204	Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. <b>2007</b> , 53, 813-22		104
203	Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure. <b>2007</b> , 53, 1289-97		64
202	Value of BNP to estimate cardiac risk in patients on cardioactive treatment in primary care. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 1178-85	12,3	10
201	Non-cardiac comorbidities in chronic heart failure. <b>2007</b> , 93, 665-71		76
200	Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. <b>2007</b> , 53, 1511-9		79
199	Biomarkers of cardiovascular damage. <b>2007</b> , 16, 247-61		32
198	Prognostic value of reduced kidney function and anemia in patients with chronic heart failure. <b>2007</b> , 8, 909-16		7
197	Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure. <b>2007</b> , 25, 335-9		28
196	Stability of IMMULITE 2000 plasma NT-proBNP in tubes with separator gel stored at room temperature. <b>2007</b> , 377, 283-4		4
195	NT-proBNP, IGF-I and survival in patients with chronic heart failure. <b>2007</b> , 17, 288-96		45

194	B-type natriuretic peptides and the general practitioner. <b>2007</b> , 50, 1702-3	2
193	Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. <b>2007</b> , 3, 413-426	124
192	Diagnosis of new onset heart failure in the community: the importance of a shared-care approach and judicious use of BNP. <b>2008</b> , 177, 197-203	2
191	Acute heart failure: new diagnostic perspectives for the emergency physician. <b>2008</b> , 3, 37-41	12
190	Aktuelle konservative Therapie der chronischen Herzinsuffizienz. <b>2008</b> , 22, 184-196	
189	The accuracy of symptoms, signs and diagnostic tests in the diagnosis of left ventricular dysfunction in primary care: a diagnostic accuracy systematic review. <b>2008</b> , 9, 56	16
188	Evidence for the use of B-type natriuretic peptides for screening asymptomatic populations and for diagnosis in primary care. <b>2008</b> , 41, 240-9	19
187	Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. <b>2008</b> , 101, 25-8	38
186	[Usefulness of natriuretic peptides in heart failure]. <b>2008</b> , 130, 591-6	3
185	Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width. <b>2008</b> , 130, 426-37	14
184	Use of B-type natriuretic peptide outside of the emergency department. <b>2008</b> , 127, 5-16	32
183	BNP or NTproBNP? A clinician's perspective. <b>2008</b> , 129, 5-14	45
182	Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department. <b>2008</b> , 101, 831-43	28
181	Natriuretic peptide testing in primary care patients. <b>2008</b> , 46, 1533-42	2
180	Prognostic threshold levels of NT-proBNP testing in primary care. <b>2009</b> , 30, 66-73	23
179	NT-proBNP response to dobutamine stress echocardiography predicts left ventricular contractile reserve in dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 475-81	12.3 7
178	Clinically relevant diagnostic research in primary care: the example of B-type natriuretic peptides in the detection of heart failure. <b>2009</b> , 26, 69-74	7
177	Biomarkers in heart failure management. <b>2008</b> , 23, 127-33	11

176	Biomarkers in heart failure management. <b>2008</b> , 7, 226-232		
175	Nurse-led heart failure follow-up in primary care in Sweden. <b>2009</b> , 8, 119-24		15
174	Comparison of the cardiac markers B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide. <b>2009</b> , 3, 465-81		11
173	Value of brain natriuretic peptides in primary care patients with the clinical diagnosis of chronic heart failure. <b>2009</b> , 43, 324-9		4
172	Bepaling van N-terminaal pro-BNP bij hartfalen: van NHG-standaard naar praktijk. <b>2009</b> , 52, 434-438		0
171	Heart failure with normal left ventricular ejection fraction. <b>2009</b> , 53, 905-18		197
170	Clinical update on nursing home medicine: 2009. <b>2009</b> , 10, 530-53		9
169	Biomarkers in heart failure: a clinical review. <b>2010</b> , 15, 251-73		19
168	Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases. <b>2010</b> , 15, 293-304		15
167	Preventing Heart Failure. <b>2010</b> , 1-26		
166	Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. <b>2010</b> , 122, 1975-96		206
165	Improvement of the cardiac marker N-terminal-pro brain natriuretic peptide through adjustment for renal function: a stratified multicenter trial. <b>2010</b> , 48, 121-8		10
164	Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure--SIGNAL-HF (Swedish Intervention study--Guidelines and NT-proBNP AnaLysis in Heart Failure). <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 1300-8	12.3	98
163	Natriuretic peptide-guided management by the general practitioner: how to interpret the SIGNAL. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 1265-7	12.3	1
162	Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. <b>2010</b> , 31, 1881-9		77
161	Comorbidities in Heart Failure. <b>2010</b> , 257-270		1
160	Usefulness of natriuretic peptides in primary health care: an exploratory study in elderly patients. <b>2010</b> , 28, 29-35		11
159	Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 518-27	12.3	84

158	Biomarkers in chronic kidney disease: a review. <b>2011</b> , 80, 806-21		268
157	A slightly elevated level of N-terminal pro-brain natriuretic peptide can predict coronary artery disease in a population with normal left ventricular function. <b>2011</b> , 26, 473-9		11
156	Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial. <b>2011</b> , 12, 12		32
155	B-type natriuretic peptide predicts long-term survival after major non-cardiac surgery. <b>2011</b> , 107, 144-9		15
154	The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. <b>2011</b> , 124, 2865-73		131
153	Applicability of current diagnostic algorithms in geriatric patients suspected of new, slow onset heart failure. <b>2012</b> , 41, 309-16		5
152	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <b>2012</b> , 22, 1787-847		3691
151	N-terminal pro brain natriuretic peptide in the management of patients in the medical emergency department (PROMPT): correlation with disease severity, utilization of hospital resources, and prognosis in a large, prospective, randomized multicentre trial. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 270-8	12.3	21
150	Development and initial validation of a simple clinical decision tool to predict the presence of heart failure in primary care: the MICE (Male, Infarction, Crepitations, Edema) rule. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 1000-8	12.3	23
149	Diagnostic value of patterns of symptoms and signs of heart failure: application of latent class analysis with concomitant variables in a cross-sectional study. <b>2012</b> , 2,		11
148	Rapid Point-of-Care NT-proBNP Optimal Cut-off Point for Heart Failure Diagnosis in Primary Care. <b>2012</b> , 65, 613-619		1
147	Diagnosis of elderly patients with heart failure. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 1097-103	12.3	36
146	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , <b>2012</b> , 14, 803-69	12.3	1892
145	Rapid point-of-care NT-proBNP optimal cut-off point for heart failure diagnosis in primary care. <b>2012</b> , 65, 613-9		22
144	The REFER (REFER for Echocardiogram) protocol: a prospective validation of a clinical decision rule, NT-proBNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design. <b>2012</b> , 12, 97		13
143	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardíaca aguda y crónica 2012. <b>2012</b> , 65, 938.e1-938.e59		27
142	¿Cómo se interpretan los péptidos natriuréticos en atención primaria?. <b>2012</b> , 19, 282-284		
141	B-type natriuretic peptide in the evaluation and management of dyspnoea in primary care. <b>2012</b> , 272, 504-13		22

140	Effect of NT-pro-BNP assay on accuracy and confidence of general practitioners in diagnosing heart failure or respiratory disease in cats with respiratory signs. <b>2012</b> , 26, 542-6	23
139	Heart Failure with Normal Left Ventricular Ejection Fraction: Basic Principles and Clinical Diagnostics. <b>2013</b> , 25-61	1
138	Effect of enhanced external counterpulsation treatment on renal function in cardiac patients. <b>2013</b> , 14, 193	7
137	Lichamelijk onderzoek en aanvullende tests bij hartfalen. <b>2013</b> , 56, 110-112	1
136	Clinical utility of biomarkers in chronic kidney disease and chronic heart failure. <b>2013</b> , 39, 128-39	1
135	Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: current status and future perspectives. <b>2013</b> , 166, 614-621.e1	8
134	Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide. <b>2013</b> , 43, 200-5	3
133	The diagnostic utility of brain natriuretic peptide in heart failure patients presenting with acute dyspnea: a meta-analysis. <b>2013</b> , 51, 1155-65	5
132	Correlative study on TCM syndromes of congestive heart failure, cardiac function and brain natriuretic peptide. <b>2013</b> ,	
131	Insuficiencia cardíaca. <b>2014</b> , 21, 9-36	
130	Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 772-7	12.3 121
129	The ratio of D-dimer to brain natriuretic peptide may help to differentiate between cerebral infarction with and without acute aortic dissection. <b>2014</b> , 340, 133-8	8
128	Elektrocardiografie in de huisartsenpraktijk. <b>2014</b> , 57, 196-200	5
127	Elektrocardiografie in de huisartsenpraktijk. <b>2014</b> , 9, 118-122	
126	Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. <b>2014</b> , 19, 439-51	41
125	Cardiac biomarkers in heart failure. <b>2014</b> , 47, 327-37	39
124	Clinical and echocardiographic characteristics of elderly hospitalized patients with high levels of NT-proBNP without clinical diagnosis of heart failure. <b>2014</b> , 26, 607-13	4
123	Biomarkers in Acute Decompensated Heart Failure. <b>2015</b> , 7, CMT.S18476	

122	A management programme for suspected heart failure in primary care in cooperation with specialists in cardiology. <b>2015</b> , 21, 26-32		5
121	Efficiently screening heart failure in patients with type 2 diabetes. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 187-95	12.3	25
120	Heart failure and chemotherapeutic agents. <b>2015</b> , 11, 453-70		5
119	INTERACTING DISCIPLINES: Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. <b>2015</b> , 4, R25-36		23
118	Heart Failure in Patients with Preserved Ejection Fraction: Questions Concerning Clinical Progression. <b>2016</b> , 3,		4
117	Extended prediction rule to optimise early detection of heart failure in older persons with non-acute shortness of breath: a cross-sectional study. <b>2016</b> , 6, e008225		4
116	Predicting cardiopulmonary involvement in patients with systemic sclerosis: complementary value of nailfold videocapillaroscopy patterns and disease-specific autoantibodies. <b>2017</b> , 56, 1081-1088		17
115	Relationship of disease-associated gene expression to cardiac phenotype is buffered by genetic diversity and chromatin regulation. <b>2016</b> , 48, 601-15		3
114	Peptidos natriuréticos: consenso y uso necesarios. <b>2016</b> , 69, 817-819		7
113	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <b>2016</b> , 37, 2129-2200		775 <sup>1</sup>
112	Consensus document and recommendations on the use of natriuretic peptides in clinical practice. <b>2016</b> , 216, 313-22		12
111	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 891-975	12.3	403 <sup>6</sup>
110	Diagnosis of heart failure. <b>2016</b> , 11, 49-50		
109	Natriuretic Peptides: Consensus Call for Use. <b>2016</b> , 69, 817-9		1
108	Consensus document and recommendations on the use of natriuretic peptides in clinical practice. <b>2016</b> , 216, 313-322		
107	Diagnostic utility of contemporary echo and BNP assessment in patients with acute heart failure during early hospitalization. <b>2016</b> , 30, 43-48		7
106	Prognostic power of NT-proBNP in left ventricular non-compaction cardiomyopathy. <b>2017</b> , 236, 321-327		17
105	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <b>2017</b> , 135, e1054-e1091		274

104	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <b>2017</b> , 23, 628-651	378
103	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <b>2017</b> , 136, e137-e161	1503
102	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <b>2017</b> , 70, 776-803	1064
101	Role of B-type natriuretic peptide (BNP) in heart failure. <b>2017</b> , 16, 3-9	1
100	Brain natriuretic peptide usefulness in very elderly dyspnoeic patients: the BED study. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 540-548	12.3 16
99	Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. <b>2017</b> , 135, 825-838	239
98	Primary care REFerral for Echocardiogram (REFER) in heart failure: a diagnostic accuracy study. <b>2017</b> , 67, e94-e102	21
97	NT-proBNP test with improved accuracy for the diagnosis of chronic heart failure. <b>2017</b> , 96, e9181	15
96	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. <b>2017</b> , 47, 555-643	44
95	In-hospital worsening heart failure: a clinically relevant endpoint?. <b>2018</b> , 5, 9-18	11
94	Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. <b>2018</b> , 5, 372-378	33
93	Accuracy, user-friendliness and usefulness of the Cobas h232 point-of-care test for NT-proBNP in primary care. <b>2018</b> , 71, 539-545	7
92	Point-of-care B-type natriuretic peptide and portable echocardiography for assessment of patients with suspected heart failure in primary care: rationale and design of the three-part Handheld-BNP program and results of the training study. <b>2018</b> , 107, 95-107	11
91	Evaluation of the effects of different treatment modalities on angiogenesis in heart failure patients with reduced/mid-range ejection fraction via VEGF and sVEGFR-1. <b>2018</b> , 39, 1028-1034	1
90	Comparison of the Diagnostic Accuracy of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients 80 Years of Age with Heart Failure. <b>2018</b> , 122, 2075-2079	3
89	Correlation between B-Type Natriuretic Peptide and N-Terminal pro-B-Type Natriuretic Peptide in a Large Japanese Population at Risk of Stage A Heart Failure. <b>2018</b> , 6, 1-8	1
88	Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis. <b>2018</b> , 361, k1450	19
87	Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides?. <b>2018</b> , 5, R65-R79	8



86	Sex Differences in the Prognostic Power of Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide for Cardiovascular Events - The Japan Morning Surge-Home Blood Pressure Study. <b>2018</b> , 82, 2096-2102		3
85	Hand-held cardiac ultrasound examinations performed in primary care patients by nonexperts to identify reduced ejection fraction. <b>2019</b> , 19, 282		4
84	Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register. <b>2019</b> , 37, 434-443		5
83	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <b>2019</b> , 40, 3297-3317		379
82	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 715-731	12.3	193
81	[Heart failure in patients over 80 years old]. <b>2019</b> , 48, 143-153		2
80	Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care. <b>2019</b> , 5, 218-224		1
79	Evaluating the diagnostic and prognostic value of biomarkers for heart disease and major adverse cardiac events in patients with muscular dystrophy. <b>2021</b> , 7, 564-573		3
78	Obesity-Related Heart Failure with Preserved Ejection Fraction: Pathophysiology, Diagnosis, and Potential Therapies. <b>2020</b> , 16, 357-368		11
77	Lung Ultrasound for Heart Failure Diagnosis in Primary Care. <b>2020</b> , 26, 824-831		6
76	Consenso de expertos sobre la insuficiencia cardiaca con fracci3n de eyecci3n reducida: m3n all3de las gu3as. <b>2020</b> , 20, 1-46		2
75	Biomarkers in atrial fibrillation and heart failure with non-reduced ejection fraction: Diagnostic application and new cut-off points. <b>2020</b> , 49, 388-392		3
74	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 391-412	12.3	84
73	The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. <b>2020</b> , 105,		3
72	Predictive Value of Electromechanical Activation Time for In-Hospital Major Cardiac Adverse Events in Heart Failure Patients. <b>2020</b> , 2020, 4532596		3
71	Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects. <b>2020</b> , 2047487319899618		3
70	Embracing the unknown: risk stratification in heart failure with preserved ejection fraction with the EPYC score. <b>2021</b> ,		
69	Enkeloedeem. <b>2021</b> , 687-701		

68	High intensity exercise during breast cancer chemotherapy - effects on long-term myocardial damage and physical capacity - data from the OptiTrain RCT. <b>2021</b> , 7, 7	3
67	Features of Diagnostics and Differential Diagnostics of Chronic Heart Failure in Outpatient Clinics.	
66	Diagnosing heart failure in primary care: individual patient data meta-analysis of two European prospective studies. <b>2021</b> , 8, 2193-2201	4
65	Biomarkers for the diagnosis and management of heart failure. <b>2021</b> , 1	11
64	Performances of a novel chemiluminescence ABEI-based NT-proBNP immunoassay. <b>2021</b> , 1-4	
63	Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme. <b>2021</b> , 9, 1-218	
62	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <b>2021</b> , 42, 3599-3726	875
61	Paraesophageal hernia repair can decrease BNP levels. <b>2021</b> , 35, 6921-6929	1
60	Use of Natriuretic Peptides in the Emergency Department and the ICU. <b>2009</b> , 523-530	0
59	Oedeem, voeten. <b>2016</b> , 801-820	2
58	What the General Practitioner Needs to Know About Their Chronic Heart Failure Patient. <b>2016</b> , 2, 79-84	7
57	Heart Failure with Preserved Ejection Fraction [A Review]. <b>2012</b> , 9, 90-95	0
56	2020 Clinical practice guidelines for Chronic heart failure. <b>2020</b> , 25, 4083	95
55	. <b>2018</b> , 58, 42-72	11
54	CLINICAL VALUE OF BLOOD BIOMARKERS IN PATIENTS WITH CHRONIC HEART FAILURE. <b>2018</b> , 8, 333-345	10
53	Amino-terminal pro-brain natriuretic peptide in children with latent rheumatic heart disease. <b>2016</b> , 9, 120-5	4
52	On the search for the right definition of heart failure with preserved ejection fraction. <b>2020</b> , 27, 449-468	5
51	A Machine Learning Approach for Chronic Heart Failure Diagnosis. <b>2021</b> , 11,	3

50 Acute Heart Failure. **2006**, 203-226

49 The ability of heart failure specialists to accurately predict NT-proBNP levels based on clinical assessment and a previous NT-proBNP measurement. **2008**, 2, 36-40

48 Use of Natriuretic Peptides in the Emergency Department and the ICU. **2009**, 523-530

47 Natriuretic Peptides. **2010**, 309-318

1

46 50 Oedeem, voeten. **2011**, 651-666

45 NHG-Standaard Hartfalen. **2011**, 459-496

3

44 Cardiac Function. **2012**, 1457-1522

1

43 Management of acute heart failure-Is there a paradigm shift around the corner?. **2013**, 03, 1-7

42 Diagnostiek van chronisch hartfalen. **2015**, 31-51

41 The REFER (REfer for Echocardiogram) study: a prospective validation and health economic analysis of a clinical decision rule, NT-proBNP or their combination in the diagnosis of heart failure in primary care. **2017**, 4, 1-56

1

40 Time trends in the use and appropriateness of natriuretic peptide testing in primary care: an observational study. **2020**, 4,

0

39 EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). **2020**, 6-76

3

38 Diagnosis, treatment, and follow-up of heart failure patients by general practitioners: A Delphi consensus statement. **2020**, 15, e0244485

1

37 Associations of NT-proBNP and hepcidin levels with clinical and laboratory parameters in patients with heart failure with various severity of left ventricular systolic dysfunction. **2020**, 19, 2587

2

36 Prognostic Value of NT-Pro Brain Natriuretic Peptide During Exercise Recovery in Ischemic Heart Failure of Reduced, Midrange, and Preserved Ejection Fraction. **2021**, 41, 282-287

1

35 NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. **2021**,

3

34 Non-targeted metabolomics identify polyamine metabolite acisoga as novel biomarker for reduced left ventricular function. **2021**,

1

33 RISK FACTORS AND QUALITY OF LIFE IN PATIENTS WITH STABLE ANGINA IN COMBINATION WITH TYPE 2 DIABETES MELLITUS AND DIFFERENT TYPES OF CHRONIC HEART FAILURE. **2021**, 3, 143

32	Chronische Herzinsuffizienz. <b>2022</b> , 501-513		
31	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. <i>European Journal of Heart Failure</i> , <b>2022</b> , 24, 4-131	12.3	50
30	Out with the Old and In with the New: Primary Care Management of Heart Failure with Preserved Ejection Fraction.. <b>2022</b> , 8, e04		0
29	Role of biomarkers in the heart failure clinic. <b>2022</b> , 37, 4-17		2
28	NT-ProBNP and high-sensitivity troponin T as screening tests for subclinical chronic heart failure in a general population.. <b>2022</b> ,		0
27	The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis.. <b>2022</b> ,		0
26	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022</b> , 101161CIR0000000000001063		35
25	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <b>2022</b> ,		49
24	Peptide for LifeSin primary care: work in progress.. <b>2021</b> ,		1
23	Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. <b>2022</b> ,		1
22	Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.. <b>2021</b> , 18, 908-951		2
21	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association.		8
20	New strategies and therapies for the prevention of heart failure in high-risk patients. <b>2022</b> , 45,		
19	Prediction of Heart Function and Volume Status in End-Stage Kidney Disease Patients through N-Terminal Pro-Brain Natriuretic Peptide. <b>2022</b> , 58, 975		
18	Prospective observational study of amino-terminal brain natriuretic peptide levels in obese and non-obese women during pregnancy.		
17	Management of heart failure with reduced ejection fraction. heartjnl-2020-318811		0
16	Los péptidos natriuréticos en el diagnóstico de la insuficiencia cardíaca en atención primaria. <b>2022</b> , 48, 101812		0
15	N-Terminal of the Prohormone Brain Natriuretic Peptide Predicts Postoperative Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation. <b>2022</b> , 11, 5493		0

- 14 Repetitive Therapie mit Levosimendan reduziert NT-proBNP und verbessert NYHA-Klasse. **2022**, 11, 484-489 ○
- 13 Prevalence and determination of risk factors of Heart Failure Preserve Ejection Fraction (HFpEF) in Type 2 Diabetes Mellitus (T2DM) population in Hospital Al-Sultan Abdullah.. ○
- 12 New Biomarkers and Their Potential Role in Heart Failure Treatment OptimisationAn African Perspective. **2022**, 9, 335 1
- 11 Natriuretic peptide testing and heart failure diagnosis in primary care: diagnostic accuracy study. BJGP.2022.0278 ○
- 10 Sex and N-terminal pro B-type natriuretic peptide: The potential mediating role of iron biomarkers. 9, ○
- 9 Risk Factors of Sudden Cardiac Arrest during the Postoperative Period in Patient Undergoing Heart Valve Surgery. **2022**, 11, 7098 ○
- 8 Prognostic Implications of Left Atrial Stiffness Index in Heart Failure Patients With Preserved Ejection Fraction. **2023**, ○
- 7 Effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide levels: A systematic review and meta-analysis. 14, ○
- 6 Heart failure and diabetes: Clinical significance and epidemiology of this two-way association. ○
- 5 Clinical Influence of Handheld Ultrasound, Supported by Automatic Quantification and Telemedicine, in Suspected Heart Failure. **2023**, 49, 1137-1144 ○
- 4 Indirect epigenetic testing identifies a diagnostic signature of cardiomyocyte DNA methylation in heart failure. **2023**, 118, 1
- 3 Interlaboratory variation for NT-proBNP among Swedish laboratories in an external quality program 2011-2021. **2023**, ○
- 2 Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis. 53, ○
- 1 Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis. 5, ○